Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
about
Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis CDaclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real lifeA Review of Daclatasvir Drug-Drug InteractionsHIV/HCV Antiviral Drug Interactions in the Era of Direct-acting AntiviralsTreatment optimization for HIV/HCV co-infected patients.Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.Daclatasvir: A Review in Chronic Hepatitis C.Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.Hepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Monoinfection TreatmentDrug interactions and antiretroviral drug monitoring.Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.Update on Hepatitis C Virus and HIV Coinfection.Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone.Recent advances in management of the HIV/HCV coinfected patient.12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIVTreatment of genotype 1 HCV infection in the HIV coinfected patient in 2014.Daclatasvir for the treatment of hepatitis C virus infection.Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients.Daclatasvir: a review of its use in adult patients with chronic hepatitis C virus infection.Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients.Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection.A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection.Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects.Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions.Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection.The safety of daclatasvir for the treatment of hepatitis C.Optimum combination therapy regimens for HIV/HCV infection.Liver involvement in human immunodeficiency virus infection.Perspectives on HCV: Current Therapeutic Regimens and Drug-Drug Interactions.Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.Drug interactions in HIV-infected patients treated for hepatitis C.Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir.Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens.Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term.Removal from liver transplantation list of an hepatitis C virus-HIV co-infected patient after successful treatment with sofosbuvir and daclatasvir.
P2860
Q26745769-9D7B0D6A-585E-405C-A14F-CB3181E4CE98Q26750628-040F28E3-89F3-493A-A3F1-A99758C154D4Q28068712-EAEEEEE5-D55E-48D2-93F7-B8EE33D95BACQ28073489-400C450D-24DC-44E0-A280-D85C124C1EF0Q30235034-944D1C9F-5344-4424-AE7C-0141F6F212A3Q30355190-017E3163-1197-41AE-91F0-93FB45702377Q30392100-E1FA215C-878E-4054-8390-475CD405A075Q33557819-3C7FB6EB-388D-48BE-9879-6B5D87C71DDEQ33576161-4E16E918-A37E-437B-B3BD-B8CD454DC27FQ34021173-24499FBB-923B-4CA5-BE67-A6E8B4E99050Q34143327-B709D834-9FC2-408D-B914-A45DEAE3CBC1Q35906047-136F0A32-7235-4E6A-9AD6-009EB4AD9651Q35960681-FEA6A36D-C88E-4C9A-A467-DB263FC04A02Q36575497-998FD090-E16D-4C83-8146-48930D2A5B5EQ36948115-9F64D171-AF7F-4E93-928C-1274ABFC6575Q37055231-2EF40340-F38F-431D-BEF0-6B4CCF36EC76Q38165816-D6ADDAEB-8900-4A98-B1C6-1E6B4C116E58Q38216586-D265B7C8-558B-4C1B-9DDC-9742B2AE6EBEQ38236179-0796E317-CBA5-4E5E-82E4-69B7D728761BQ38365658-B63179B7-2303-42A5-ADE0-9BD090D4CA5AQ38377264-DEB12F2C-7C05-4EF9-B562-D39987A30E00Q38503778-61F9826C-6D3C-4FFD-920A-16B288380ACAQ38512161-5F28579F-7384-40DC-9912-4AB546DB5D31Q38554604-D28813DF-765D-4CE2-8335-7D71118E9FEDQ38612647-49100C1D-DAD0-492E-B7A3-16DB6A4A6454Q38621245-FF0FBF3C-754C-4A93-A3C8-857AA00FDC58Q38631256-630EDB13-0328-4E76-A44B-19298B8A4E71Q38634221-AF706823-8821-435D-967C-AA923F0FA494Q38715477-8450C34B-3A1B-46EA-9DC7-6DBFBD01CC45Q38852184-E423DCD4-BD2B-48FA-8F4D-3C94C6DED80EQ38927205-F95D5885-39B4-44F6-9A08-62EE1F3B319CQ38929010-B3116226-07B1-4FBF-8EE4-8879C3246820Q40143109-8AC7DB32-F3E3-4C46-8628-BBCDD39D23DFQ40328514-F8EAC966-8DEE-4415-B9F9-538B6851CF44Q40494843-40875063-2F78-4FAB-9521-F6D095E13B9FQ40893681-1C949AFB-5212-47A5-800B-9DE63CC6CBFFQ41578791-A65A50BA-139F-4B12-A5CB-E695754D3B2DQ43881640-AB3E3ABB-AAF9-415A-BDAA-B32C26891720
P2860
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Assessment of pharmacokinetic ...... avir, efavirenz and tenofovir.
@en
Assessment of pharmacokinetic ...... avir, efavirenz and tenofovir.
@nl
type
label
Assessment of pharmacokinetic ...... avir, efavirenz and tenofovir.
@en
Assessment of pharmacokinetic ...... avir, efavirenz and tenofovir.
@nl
prefLabel
Assessment of pharmacokinetic ...... avir, efavirenz and tenofovir.
@en
Assessment of pharmacokinetic ...... avir, efavirenz and tenofovir.
@nl
P2093
P356
P1433
P1476
Assessment of pharmacokinetic ...... avir, efavirenz and tenofovir.
@en
P2093
Berend Oosterhuis
Carey Hwang
Dennis Grasela
Hamza Kandoussi
Heather Sevinsky
Jan Hartstra
Marc Bifano
Maria Velinova-Donga
Renger Tiessen
Richard Bertz
P304
P356
10.3851/IMP2674
P577
2013-08-20T00:00:00Z